1. Home
  2. LXEO vs EMBC Comparison

LXEO vs EMBC Comparison

Compare LXEO & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$7.65

Market Cap

731.3M

Sector

N/A

ML Signal

HOLD

Logo Embecta Corp.

EMBC

Embecta Corp.

HOLD

Current Price

$12.14

Market Cap

755.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXEO
EMBC
Founded
2017
1924
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
731.3M
755.0M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
LXEO
EMBC
Price
$7.65
$12.14
Analyst Decision
Strong Buy
Buy
Analyst Count
10
2
Target Price
$18.60
$18.50
AVG Volume (30 Days)
1.3M
447.3K
Earning Date
11-05-2025
02-05-2026
Dividend Yield
N/A
4.97%
EPS Growth
N/A
20.90
EPS
N/A
1.62
Revenue
N/A
$1,080,400,000.00
Revenue This Year
N/A
$2.00
Revenue Next Year
N/A
$0.27
P/E Ratio
N/A
$7.46
Revenue Growth
N/A
N/A
52 Week Low
$1.45
$9.20
52 Week High
$10.99
$19.67

Technical Indicators

Market Signals
Indicator
LXEO
EMBC
Relative Strength Index (RSI) 39.22 45.21
Support Level $7.02 $12.01
Resistance Level $10.75 $13.03
Average True Range (ATR) 0.84 0.45
MACD -0.24 0.01
Stochastic Oscillator 18.70 46.06

Price Performance

Historical Comparison
LXEO
EMBC

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Share on Social Networks: